ARTICLE | Clinical News
Acclaim: Phase II failed
February 7, 2005 8:00 AM UTC
In a double-blind, placebo-controlled, international Phase II trial in 204 patients, Acclaim missed the primary endpoint of significant increase in TWT compared to nitrate therapy alone. The company w...